This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD hours. CPD dashboard

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD hours. Upgrade to Pro

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD hours. CPD dashboard

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD hours. Upgrade to Pro

Management

Authoring team

Consult expert advice.

Once the underlying precipitating cause has been identified and treated (such as early targeted antimicrobial therapy and source control in pneumonia or sepsis), management aims to achieve adequate gas exchange while avoiding ventilator-induced lung injury (VILI) and fluid overload.

Core evidence-based therapies (1, 4):

  • lung-protective mechanical ventilation:
    • ventilation with low tidal volumes (6 mL/kg of predicted body weight) and limiting plateau pressure to <= 30 cmH2O reduces mortality by mitigating volutrauma and biotrauma
    • further reduction of tidal volume using extracorporeal carbon dioxide removal is not recommended outside clinical trials
  • positive end-expiratory pressure (PEEP):
    • PEEP prevents repetitive alveolar opening and closing (atelectrauma), although higher intrathoracic pressures may compromise cardiac output or cause barotrauma
    • higher PEEP (while maintaining plateau pressure <= 30 cmH2O) may be considered in moderate-to-severe ARDS (PaO2/FiO2 < 200 mmHg), whereas sustained high-pressure recruitment manoeuvres and high-frequency oscillatory ventilation should be avoided
  • prone positioning:
    • early, prolonged prone-positioning sessions (>= 16 hours per day) reduce mortality in intubated patients with moderate-to-severe ARDS (PaO2/FiO2 < 150 mmHg) by improving ventilation-perfusion matching and reducing dorsal lung compression
    • awake prone positioning is also used in nonintubated patients with acute hypoxaemic respiratory failure
  • fluid management:
    • conservative fluid management (maintaining a neutral-to-negative fluid balance or active deresuscitation once shock has resolved) reduces pulmonary oedema, increases ventilator-free days, and shortens intensive care unit stay compared with liberal fluid administration
  • adjunctive and rescue therapies:
    • neuromuscular blockade (e.g. short-course cisatracurium) may be considered in moderate-to-severe ARDS (PaO2/FiO2 < 150 mmHg) for severe ventilator dyssynchrony, refractory hypoxaemia, or high barotrauma risk, though routine early use has not shown consistent survival benefit
    • venovenous extracorporeal membrane oxygenation (ECMO) in specialist centres is reserved for patients with refractory hypoxaemia or severe respiratory acidosis despite optimal lung-protective ventilation, prone positioning, and neuromuscular blockade
    • routine inhaled nitric oxide should generally be avoided except as a rescue measure for life-threatening hypoxaemia

Pre-intubation respiratory support (4):

  • high-flow nasal oxygen (HFNO) and noninvasive ventilation (NIV) are used in nonintubated patients with hypoxaemic respiratory failure, with HFNO shown to be noninferior to NIV in acute respiratory failure
  • clinicians must monitor closely for excessive inspiratory effort and patient self-inflicted lung injury, weighing these risks against those of endotracheal intubation and invasive ventilation

Steroids in ARDS:

  • data from clinical trials do not support the use of short-course, high-dose corticosteroids for preventing ARDS or for the treatment of early ARDS (2)
  • a systematic review found that the use of low-dose corticosteroids was associated with improved mortality and morbidity outcomes without increased adverse reactions (3)
  • in COVID-19-related ARDS, dexamethasone reduces mortality in mechanically ventilated patients and is established standard care; in non-COVID-19 ARDS, systematic reviews suggest a modest survival benefit when administered early, though routine use remains under investigation in ongoing trials (4)

Reference:

  1. Rawal G, Yadav S, Kumar R. Acute Respiratory Distress Syndrome: An Update and Review. J Transl Int Med. 2018;6(2):74-77. Published 2018 Jun 26. doi:10.1515/jtim-2016-0012
  2. Deal EN et al. Role of corticosteroids in the management of acute respiratory distress syndrome. Clinical Therapeutics 2008;30(5): 787-799.
  3. Tang BM et al. Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: a systematic review and meta-analysis. Crit Care Med. 2009 May;37(5):1594-603.
  4. Calfee CS, McAuley DF. Acute Respiratory Distress Syndrome. N Engl J Med. 2026;395(20):2027-2042. doi:10.1056/NEJMra2601172.

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.